Safety, Tolerability, PK Profile, and Symptom Response of a 7-Day Dosing With 25 mg or 50 mg Daily of REL-1017 in MDD
Study sponsor: Relmada Therapeutics, Inc. · RLMD
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2019-07-30Actual
Enrollment · participants62Actual
Source updated2023-11-01Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.